BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stake Lowered by Teza Capital Management LLC

Teza Capital Management LLC trimmed its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 9.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,874 shares of the biotechnology company’s stock after selling 4,864 shares during the period. Teza Capital Management LLC’s holdings in BioCryst Pharmaceuticals were worth $360,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $46,000. R Squared Ltd bought a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $48,000. KBC Group NV lifted its stake in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 4,537 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $80,000. Finally, Syon Capital LLC bought a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $99,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. raised their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, May 6th. JMP Securities reissued a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Needham & Company LLC raised their price objective on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald began coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an “overweight” rating and a $20.00 price target on the stock. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.56.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $10.33 on Wednesday. The stock has a 50-day simple moving average of $8.22 and a 200 day simple moving average of $7.99. BioCryst Pharmaceuticals, Inc. has a twelve month low of $5.92 and a twelve month high of $11.11. The stock has a market capitalization of $2.16 billion, a PE ratio of -16.93 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. As a group, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.